Glioblastoma Pipeline Outlook Report 2024 (Updated)

June 05 21:03 2024
Glioblastoma Pipeline Outlook Report 2024 (Updated)

DelveInsight’s, “Glioblastoma Pipeline Insight, 2024,” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Glioblastoma Pipeline Report

  • DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
  • The leading Glioblastoma Companies such as Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience, Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
  • Promising Glioblastoma Therapies such as Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.
  • May 2024:- Centre Antoine Lacassagne- A Phase I/II Study of Pazopanib in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme After Surgery and RT-CT. A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study).
  • May 2024:- Chirag G.Patil- The purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab and radiation therapy before surgical resection in patients with recurrent glioblastoma as defined by treatment-related AEs and the number of patients who do not necessitate a delay in surgical resection, and to assess overall survival. The secondary objectives are to assess progression free survival, and to assess the T cell clonality, CD8 T cell activation and Tumor Infiltrating Lymphocyte (TIL) score after treatment.
  • May 2024:- Cantex Pharmaceuticals- This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There’s no cure for glioblastoma, which is also known as glioblastoma multiforme. Treatments, including surgery, radiation, and chemotherapy might slow cancer growth and reduce symptoms.

 

Explore our comprehensive Glioblastoma Pipeline Report to stay informed about the latest advancements. Download copy now @ Glioblastoma Pipeline Outlook

 

Glioblastoma Overview

Glioblastoma, often referred to as glioblastoma multiforme (GBM), is an aggressive and malignant form of brain tumor that originates in the glial cells of the brain. It is categorized as a grade IV astrocytoma, characterized by its rapid growth and invasive nature within the brain tissue. Glioblastomas are notorious for their resistance to treatment and high recurrence rates despite aggressive therapies such as surgery, radiation, and chemotherapy. Symptoms vary depending on the tumor’s location but commonly include headaches, nausea, cognitive impairment, and neurological deficits. The prognosis for glioblastoma remains challenging, with most patients facing a median survival of approximately 12 to 15 months after diagnosis, highlighting the urgent need for continued research into more effective treatments and therapies.

 

Glioblastoma Emerging Drugs Profile

  • Enzastaurin: Denovo BioPharma

DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world’s first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM).

  • Tofacitinib: Pfizer

Tofacitinib (Xeljanz, Jaquinus) is an immunosuppressant. It is a first-generation, orally bioavailable pan-Jak inhibitor. Tofacitinib was mainly developed for use as an immunosuppressant for organ transplantation and possibly for the treatment of autoimmune diseases. Tofacitinib suppresses the Jak family members at IC50s as follows: Jak1, Jak2, and Jak3, in a cell-free kinase assay. In addition, Tofacitinib effectively suppresses common γ-chain cytokines involving IL-2, IL-4, IL-15 and IL-21. Furthermore, the most common side effects include headaches, upper respiratory infections, diarrhea, and nasopharyngeal inflammation, elevation in low-density lipoprotein and cholesterol levels and reduction in neutrophil numbers. Serious infections including pneumonia, cellulitis and urinary tract infections have been described in patients treated with Tofacitinib. Currently, the drug is in the Phase III stage of its development for the treatment of glioblastoma multiforme.

  • VT1021: Vigeo Therapeutics

Vigeo’s lead asset, VT1021, is a first-in-class dual modulating compound that blocks the CD47 immune checkpoint and activates CD36, which induces apoptosis and increases the M1:M2 macrophage ratio. VT1021 achieves this through stimulation of thrombospondin-1 (Tsp-1). The goal of these dual-modulating effects is conversion of immuno-suppressive, or “cold,” tumors that don’t respond to immuno-oncology agents, to immuno-stimulated, or “hot,” tumors that are potentially more receptive to immuno-oncology agents. Vigeo is developing VT1021 as a therapeutic agent across a range of cancers, with a current focus on solid tumors. Vigeo Therapeutics is advancing VT1021 into a Phase II/III registrational study through the company’s collaboration with the Global Coalition for Adaptive Research (GCAR).

  • Varlilumab: Celldex Therapeutics

Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses and may result in fewer toxicities due to its restricted expression and regulation.

Varlilumab is a potent anti-CD27 agonist that induces activation and proliferation of human T cells when combined with T cell receptor stimulation. Varlilumab has completed a Phase I dose-escalation study, demonstrating potent immunologic activity consistent with its mechanism of action and anti-tumor activity in patients with advanced, refractory disease. No maximum tolerated dose was reached and minimal toxicities were observed. Celldex initiated a broad development program for varlilumab to explore its role as an immune activator in combination with a number of complementary investigational and approved oncology drugs. Currently, the drug is in the Phase II stage of its development for the treatment of glioblastoma multiforme.

  • Debio 0123: Debiopharm

Debio 0123 is a Wee1 kinase inhibitor. The compound is being developed based on the deepened understanding of the DNA damage response (DDR) of cancer cells. Inhibition of WEE1 prevents cells to arrest or repair DNA damages and force them to prematurely continue through the cell cycle, therefore accumulating unrepaired DNA damages ultimately leading to cell death. The compound is being developed in light of the need to improve cancer patients’ treatment response and to overcome treatment resistance to current therapies. Pre-clinical models have shown anti-tumor activity both as a single agent and in combination with carboplatin. The advancement of Debio 0123 into clinical studies will assess the therapeutic results for cancer patients in various tumor types. Currently, the drug is in the Phase I/II stage of its development for the treatment of Glioblastoma.

  • PRT3645: Prelude Therapeutics

PRT3645 is Prelude’s next generation CDK4/6 inhibitor with high tissue distribution and brain penetration. In preclinical studies, PRT3645 treatment resulted in concentration-dependent inhibition of cell proliferation in both glioblastoma (GBM) cell lines and in ER+/HER2- and HER2+ breast cancer lines. In vivo, orally administered PRT3645 was well tolerated and highly efficacious in a dose-dependent manner in orthotopic human breast cancer brain metastasis and GBM models. Currently, the drug is in the Phase I stage of its development for the treatment of Glioblastoma.

 

Dive into our Glioblastoma Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Glioblastoma Treatment Therapies

 

Glioblastoma Therapeutics Assessment

There are approx. 195+ key companies which are developing the therapies for Glioblastoma. The Glioblastoma companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma.

 

DelveInsight’s Glioblastoma pipeline report covers around 210+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Download the Glioblastoma Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Glioblastoma Clinical Trials Assessment

 

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Glioblastoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy 

 

Dive into our detailed Glioblastoma Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Glioblastoma Products, Companies, and Unmet Needs

 

Scope of the Glioblastoma Pipeline Report

  • Coverage- Global
  • Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience, Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
  • Glioblastoma Therapies- Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.

 

Gain valuable insights into emerging therapies and innovations with our Glioblastoma Pipeline Report @ Glioblastoma Market Drivers and Barriers, Future Perspectives and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Glioblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Glioblastoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Enzastaurin: Denovo BioPharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Varlilumab: Celldex Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PRT3645: Prelude Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ELC-401: Elicera Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Glioblastoma Key Companies
  21. Glioblastoma Key Products
  22. Glioblastoma- Unmet Needs
  23. Glioblastoma- Market Drivers and Barriers
  24. Glioblastoma- Future Perspectives and Conclusion
  25. Glioblastoma Analyst Views
  26. Glioblastoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: